• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 419674 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1417183859 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1417183859 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Buyers Accumulating Shares of Spectrum Pharmaceuticals on 1.2x Above-Average Volume (SPPI)

Published on Thu, 01/10/2013 - 14:13
By Peter Chu

Shares of Spectrum Pharmaceuticals are trading up 3.1% to $13.00 today on above average volume. Today's volume of 1.1 million shares tops the average 30-day volume of 918,000 shares. Spikes in volume can validate a breakout or signify a potential turning point.

Potential upside of 70.8% exists for Spectrum Pharmaceuticals, based on a current level of $13.00 and analysts' average consensus price target of $22.20. The stock should discover initial support at its 200-day moving average (MA) of $12.20 and subsequent support at its 50-day MA of $11.29.

In the past 52 weeks, shares of Spectrum Pharmaceuticals have traded between a low of $9.31 and a high of $17.48 and are now at $13.00, which is 40% above that low price. Over the past week, the 200-day moving average (MA) has remained constant while the 50-day MA has advanced 0.4%.

Spectrum Pharmaceuticals Inc. develops in-licensed drugs for the treatment and supportive care of cancer patients. The Company's satraplatin is an oral, anti-cancer drug. Spectrum's Elsamitrucin targets non-Hodgkin's lymphoma, and Neoquin is being studied in the treatment of superficial bladder cancer. Spectrum also has a pipeline of pre-clinical neurological drug candidates.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Possible Bearish Inside Day Candle Patte...

Analyzing the price chart for Randgold Resources (NASDAQ:GOLD) has revealed a potentia ...

Possible Bearish Inside Day Candle Patte...

Analysts have spotted a possible bearish inside day candle pattern in DSW (NYSE:DSW) ba ...

Possible Bearish Inside Day Candle Patte...

Analyzing the price chart for Rayonier (NYSE:RYN) has revealed a potential bearish ins ...

Possible Bearish Inside Day Candle Patte...

Analyzing the price chart for Accenture (NYSE:ACN) has revealed a potential bearish in ...

Possible Bearish Inside Day Candle Patte...

Analysts have spotted a possible bearish inside day candle pattern in New Gold (AMEX:NG ...

Bottom 5 Companies in the Trucking Indus...

Analysis was conducted on the Trucking industry to measure relative performance to find ...

Short-term Underperformance Detected in ...

Analysis was conducted on the Systems Software industry to measure relative performance ...

AK Steel Holding had the Lowest Relative...

Here are 5 stocks in the Steel industry ranked by performance. We compiled the trading ...